You are here

  • Home
  • Archive
  • Volume 10, Issue 5
  • Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity

Article info

Article menu
Basic tumor immunology
Original research
Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity

Authors

  • Pierre-Louis Bernard Immunity and Cancer Team, Onco-Hemato Immuno-Onco Department, OHIO, Institut Paoli-Calmettes, Inserm, CNRS, Cancer Research Centre, CRCM, Marseille, France PubMed articlesGoogle scholar articles
  • Rebecca Delconte Immunology Program, Sloan-Kettering Institute, New York City, New York, USA PubMed articlesGoogle scholar articles
  • Sonia Pastor Immunity and Cancer Team, Onco-Hemato Immuno-Onco Department, OHIO, Institut Paoli-Calmettes, Inserm, CNRS, Cancer Research Centre, CRCM, Marseille, France PubMed articlesGoogle scholar articles
  • Vladimir Laletin Immunity and Cancer Team, Onco-Hemato Immuno-Onco Department, OHIO, Institut Paoli-Calmettes, Inserm, CNRS, Cancer Research Centre, CRCM, Marseille, France PubMed articlesGoogle scholar articles
  • Cathy Costa Da Silva Immunity and Cancer Team, Onco-Hemato Immuno-Onco Department, OHIO, Institut Paoli-Calmettes, Inserm, CNRS, Cancer Research Centre, CRCM, Marseille, France PubMed articlesGoogle scholar articles
  • Armelle Goubard Immunity and Cancer Team, Onco-Hemato Immuno-Onco Department, OHIO, Institut Paoli-Calmettes, Inserm, CNRS, Cancer Research Centre, CRCM, Marseille, France PubMed articlesGoogle scholar articles
  • Emmanuelle Josselin Immunity and Cancer Team, Onco-Hemato Immuno-Onco Department, OHIO, Institut Paoli-Calmettes, Inserm, CNRS, Cancer Research Centre, CRCM, Marseille, France PubMed articlesGoogle scholar articles
  • Rémy Castellano Immunity and Cancer Team, Onco-Hemato Immuno-Onco Department, OHIO, Institut Paoli-Calmettes, Inserm, CNRS, Cancer Research Centre, CRCM, Marseille, France PubMed articlesGoogle scholar articles
  • Adrien Krug INSERM, Unité 1111, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, Unité Mixte de Recherche (UMR) 5308, CIRI-International Center for Infectiology Research, Nice, France PubMed articlesGoogle scholar articles
  • Julien Vernerey Immunity and Cancer Team, Onco-Hemato Immuno-Onco Department, OHIO, Institut Paoli-Calmettes, Inserm, CNRS, Cancer Research Centre, CRCM, Marseille, France PubMed articlesGoogle scholar articles
  • Raynier Devillier Immunity and Cancer Team, Onco-Hemato Immuno-Onco Department, OHIO, Institut Paoli-Calmettes, Inserm, CNRS, Cancer Research Centre, CRCM, Marseille, France PubMed articlesGoogle scholar articles
  • Daniel Olive Immunity and Cancer Team, Onco-Hemato Immuno-Onco Department, OHIO, Institut Paoli-Calmettes, Inserm, CNRS, Cancer Research Centre, CRCM, Marseille, France PubMed articlesGoogle scholar articles
  • Els Verhoeyen INSERM, Unité 1111, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, Unité Mixte de Recherche (UMR) 5308, CIRI-International Center for Infectiology Research, Nice, France PubMed articlesGoogle scholar articles
  • Eric Vivier Innate Pharma Research Labs, Innate Pharma; Centre d'Immunologie de Marseille-Luminy, CIML; Service d'Immunologie, Marseille Immunopole, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Aix Marseille Université, Inserm, CNRS, Marseille, France PubMed articlesGoogle scholar articles
  • Nicholas D Huntington Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia PubMed articlesGoogle scholar articles
  • Jacques Nunes Immunity and Cancer Team, Onco-Hemato Immuno-Onco Department, OHIO, Institut Paoli-Calmettes, Inserm, CNRS, Cancer Research Centre, CRCM, Marseille, France PubMed articlesGoogle scholar articles
  • Geoffrey Guittard Immunity and Cancer Team, Onco-Hemato Immuno-Onco Department, OHIO, Institut Paoli-Calmettes, Inserm, CNRS, Cancer Research Centre, CRCM, Marseille, France PubMed articlesGoogle scholar articles

Citation

Bernard P, Delconte R, Pastor S, et al
Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity
Journal for ImmunoTherapy of Cancer 2022;10:e004244. doi: 10.1136/jitc-2021-004244
Online issue publication 
May 19, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.